Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer

26 Feb 2022

Abstract excerpt

Metformin is currently a strong candidate anti-tumor agent in multiple cancers. However, its anti-tumor effectiveness varies among different cancers or subpopulations, potentially due to tumor heterogeneity. It thus remains unclear which hepatocellular carcinoma (HCC) patient subpopulation(s) can benefit from metformin treatment. Here, through a genome-wide CRISPR-Cas9-based knockout screen, we find that DOCK1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Metabolism, Diabetes, and Cancer
Share to Pancreatic function and diabetes
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35217990
DOI: 10.1007/s13238-022-00906-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancerPMID 35217990Read ↗

A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivoSemantic proximity Read ↗

Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1Semantic proximity Read ↗

Metformin decreases <i>Cyp26a1</i> to prevent hepatocarcinogenesis through down- regulating CD8 <sup>+</sup> T cellsSemantic proximity Read ↗

First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal CancerSemantic proximity Read ↗

Multiplexed mosaic tumor models reveal natural phenotypic variations in drug response within and between populationsSemantic proximity Read ↗

The anticancer effect of Metformin targets VDAC1 via ER-mitochondria interaction-mediated autophagy in HCCSemantic proximity Read ↗

Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines.Semantic proximity Read ↗

Deletion of epithelial HKDC1 decelerates cellular proliferation and impairs mitochondrial function of tumorous epithelial cells thereby protecting from intestinal carcinogenesis in miceSemantic proximity Read ↗

Caspase-1 regulates TBK1 and PPARα to suppress steatosis-associated hepatocarcinogenesisSemantic proximity Read ↗

Inhibition of Mitochondrial Dynamics by Mitochondrial Division Inhibitor-1 Suppresses Cell Migration and Metastatic Markers in Colorectal Cancer HCT116 CellsSemantic proximity Read ↗

CRISPR screens reveal MCT1-driven metabolic escape from SMAD3 inhibition as a therapeutic vulnerabilitySemantic proximity Read ↗

Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.